Skip to content
Menu

Oppenheimer Maintains Perform on Acadia Pharmaceuticals, Lowers Price Target to $21

Benzinga Newsdesk 10 hours ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Oppenheimer analyst Matthew Hershenhorn maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Perform and lowers the price target from $23 to $21.

Oppenheimer analyst Matthew Hershenhorn maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Perform and lowers the price target from $23 to $21.

Read at benzinga.com